FDA Nod Makes Boehringer Ingelheim Drug an Alternative to AstraZeneca ADC in Lung Cancer
Boehringer-Ingelheim pill Hernexeos was awarded accelerated FDA approval for advanced cases of non-small cell lung cancer with HER2 mutations. But Bayer is on its heels with an oral small molecule currently under FDA review in the same indication.